Terumo Corp. (OTCMKTS:TRUMY – Get Free Report)’s share price gapped down before the market opened on Friday following a dissappointing earnings announcement. The stock had previously closed at $15.78, but opened at $14.94. Terumo shares last traded at $15.0450, with a volume of 3,068 shares changing hands.
The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The company had revenue of $1.96 billion for the quarter, compared to analyst estimates of $1.94 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%.
Wall Street Analysts Forecast Growth
TRUMY has been the topic of a number of research reports. Zacks Research raised Terumo from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. Nomura upgraded Terumo from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, Terumo has an average rating of “Strong Buy”.
Get Our Latest Research Report on Terumo
Terumo Stock Down 4.8%
The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $22.16 billion, a P/E ratio of 21.15 and a beta of 0.82. The stock’s 50-day simple moving average is $14.81 and its 200-day simple moving average is $14.08.
Terumo Company Profile
Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.
Featured Stories
- Five stocks we like better than Terumo
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
